Vyne Therapeutics Inc VYNE.OQ VYNE.O is expected to show a rise in quarterly revenue when it reports results on February 26 (estimated) for the period ending December 31 2024
The Bridgewater New Jersey-based company is expected to report a 84.2% increase in revenue to $140 thousand from $76 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Vyne Therapeutics Inc is for a loss of 30 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Vyne Therapeutics Inc is $5.88, above its last closing price of $2.74.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.23 | -0.23 | -0.29 | Missed | -23.4 |
Jun. 30 2024 | -0.19 | -0.19 | -0.22 | Missed | -15.8 |
Mar. 31 2024 | -0.24 | -0.24 | -0.15 | Beat | 37.5 |
Dec. 31 2023 | -0.50 | -0.50 | -0.20 | Beat | 60 |
Sep. 30 2023 | -0.76 | -0.76 | -2.01 | Missed | -164.5 |
Jun. 30 2023 | -1.99 | -1.99 | -3.09 | Missed | -55.3 |
Mar. 31 2023 | -2.59 | -2.61 | -1.74 | Beat | 33.3 |
Dec. 31 2022 | -3.24 | -3.24 | -3.33 | Missed | -2.8 |
This summary was machine generated February 24 at 14:19 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。